Lewes, DE -- (SBWIRE) -- 10/30/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Cell Therapeutics Inc (NASDAQ:CTIC), Exelixis, Inc. (NASDAQ:EXEL), Real Goods Solar, Inc. (NASDAQ:RSOL), VIVUS, Inc. (NASDAQ:VVUS)
Cell Therapeutics Inc (NASDAQ:CTIC) opened its shares at the price of $1.88 for the day. Its closing price was $1.89 after gaining +1.61% for the day. The company traded with the total volume of 2.44 million shares, while its average trading volume remained 3.62 million shares. The beta of CTIC stands at5.29. Cell Therapeutics, Inc. engages in the acquisition, development, and commercialization of treatments for cancer.
For How Long CTIC will Fight for Profitability? Read This Trend Analysis report
Exelixis, Inc.(NASDAQ:EXEL) percentage change plunged -1.02% to close at $5.34 with the total traded volume of 2.42 million shares, and average volume of 2.06 million. The 52 week range of the stock remained $2.42 - $2.06, while its day lowest price was $5.33 and it hit its day highest price at $5.49.
Has EXEL Found The Bottom and Ready To Move Up? Find Out Here
Real Goods Solar, Inc. (NASDAQ:RSOL) started its trading session with the price of $3.42 and closed at $3.42 by scoring +0.59%. RSOL’s stocks traded with total volume of 2.31 million shares, while the average trading volume remained 4.75 million shares. The beta of RSOL stands at 1.02. Day range of the stock was $3.27 -$3.55. Real Goods Solar, Inc. operates as a residential and commercial solar energy engineering, procurement, and construction company in the United States.
For How Long RSOL will Fight for Profitability? Read This Trend Analysis report
VIVUS, Inc. (NASDAQ:VVUS) ended its day with the gain of +1.36% and closed at the price of $9.72 after opening at $9.66. Stock traded during its last trading session with the total volume of 2.27 million shares, as compared to its average volume of 2.76 million shares. VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health.
For How Long VVUS’s Gloss will Attract Investors? Find out via this report
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)